{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Yttrium-90+ibritumomab+tiuxetan", "query": { "intervention": "Yttrium-90 ibritumomab tiuxetan" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 63, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Yttrium-90+ibritumomab+tiuxetan&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-06T06:18:56.780Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00493467", "title": "Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Ibritumomab Tiuxetan (Zevalin)", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2006-06", "completion_date": "2022-08-11", "has_results": true, "last_update_posted_date": "2022-09-15", "last_synced_at": "2026-10-06T06:18:56.780Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00493467" }, { "nct_id": "NCT04189588", "title": "Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Oncology Patients Receiving Chemotherapy" ], "interventions": [ { "name": "Cetirizine HCl 10 mg/mL", "type": "DRUG" }, { "name": "Diphenhydramine 50 mg/mL", "type": "DRUG" }, { "name": "anti-CD20 such as Rituximab or Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TerSera Therapeutics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2020-03-25", "completion_date": "2020-12-23", "has_results": true, "last_update_posted_date": "2023-10-06", "last_synced_at": "2026-10-06T06:18:56.780Z", "location_count": 7, "location_summary": "Napa, California • Rancho Mirage, California • Santa Rosa, California + 4 more", "locations": [ { "city": "Napa", "state": "California" }, { "city": "Rancho Mirage", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Houston", "state": "Texas" }, { "city": "Round Rock", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04189588" }, { "nct_id": "NCT01973062", "title": "Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Central Nervous System Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "yttrium Y 90 ibritumomab tiuxetan", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2014-03", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2020-07-24", "last_synced_at": "2026-10-06T06:18:56.780Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01973062" }, { "nct_id": "NCT00005592", "title": "Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "90-Y-ibritumomab tiuxetan", "type": "BIOLOGICAL" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "indium In 111 ibritumomab tiuxetan", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "1999-11", "completion_date": "2005-11", "has_results": false, "last_update_posted_date": "2015-10-21", "last_synced_at": "2026-10-06T06:18:56.780Z", "location_count": 2, "location_summary": "Birmingham, Alabama • Washington D.C., District of Columbia", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005592" }, { "nct_id": "NCT00290511", "title": "Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Mitoxantrone", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Zevalin", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 49, "start_date": "2004-06-29", "completion_date": "2021-02-12", "has_results": true, "last_update_posted_date": "2022-04-22", "last_synced_at": "2026-10-06T06:18:56.780Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00290511" }, { "nct_id": "NCT01234766", "title": "Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, Follicular" ], "interventions": [ { "name": "Bendamustine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Y-90 ibritumomab", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2010-10", "completion_date": "2021-04-01", "has_results": true, "last_update_posted_date": "2021-05-18", "last_synced_at": "2026-10-06T06:18:56.780Z", "location_count": 4, "location_summary": "Scarborough, Maine • Lebanon, New Hampshire • Durham, North Carolina + 1 more", "locations": [ { "city": "Scarborough", "state": "Maine" }, { "city": "Lebanon", "state": "New Hampshire" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT01234766" }, { "nct_id": "NCT00012298", "title": "Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Nodal Marginal Zone B-cell Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Small Lymphocytic Lymphoma", "Splenic Marginal Zone Lymphoma", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "yttrium Y 90 ibritumomab tiuxetan", "type": "BIOLOGICAL" }, { "name": "indium In 111 ibritumomab tiuxetan", "type": "BIOLOGICAL" }, { "name": "oprelvekin", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 81, "start_date": "2001-04", "completion_date": "2010-04", "has_results": true, "last_update_posted_date": "2018-08-09", "last_synced_at": "2026-10-06T06:18:56.780Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00012298" }, { "nct_id": "NCT01359592", "title": "S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "R-CHOP regimen", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "fludeoxyglucose F 18", "type": "RADIATION" }, { "name": "selective external radiation therapy", "type": "RADIATION" }, { "name": "yttrium Y 90 ibritumomab tiuxetan", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER", "RADIATION" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 159, "start_date": "2011-09", "completion_date": "2023-12", "has_results": true, "last_update_posted_date": "2025-06-17", "last_synced_at": "2026-10-06T06:18:56.780Z", "location_count": 240, "location_summary": "Anchorage, Alaska • Tucson, Arizona • Aurora, Colorado + 153 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boulder", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01359592" }, { "nct_id": "NCT00089284", "title": "Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Hodgkin's Lymphoma (NHL)" ], "interventions": [ { "name": "Rituxan", "type": "DRUG" }, { "name": "motexafin gadolinium", "type": "DRUG" }, { "name": "111Indium-Zevalin and 90Yttrium-Zevalin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2003-10-28", "completion_date": "2008-08-20", "has_results": true, "last_update_posted_date": "2019-08-14", "last_synced_at": "2026-10-06T06:18:56.780Z", "location_count": 2, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00089284" }, { "nct_id": "NCT00384111", "title": "Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Follicular Lymphoma", "Lymphoma, Follicular" ], "interventions": [ { "name": "Zevalin Therapeutic Regimen", "type": "DRUG" }, { "name": "R-CVP", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Spectrum Pharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2006-10", "completion_date": "2008-11", "has_results": true, "last_update_posted_date": "2022-01-14", "last_synced_at": "2026-10-06T06:18:56.780Z", "location_count": 6, "location_summary": "Jacksonville, Florida • St. Petersburg, Florida • Marietta, Georgia + 3 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Chattanooga", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00384111" } ] }